Go back to Resources

Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial

Sep-24

Journal Article

Authors:

Fong, Y.

Dang, L.

Zhang, B.

Fintzi, J.

Chen, S.

Wang, J.

Rouphael, N. G.

Branche, A. R.

Diemert, D. J.

Falsey, A. R.

Losada, C.

Baden, L. R.

Frey, S. E.

Whitaker, J. A.

Little, S. J.

Kamidani, S.

Walter, E. B.

Novak, R. M.

Rupp, R.

Jackson, L. A.

Yu, C.

Magaret, C. A.

Molitor, C.

Borate, B.

Babu, T. M.

Kottkamp, A. C.

Luetkemeyer, A. F.

Immergluck, L. C.

Presti, R. M.

Backer, M.

Winokur, P. L.

Mahgoub, S. M.

Goepfert, P. A.

Fusco, D. N.

Atmar, R. L.

Posavad, C.

Mu, J.

Makowski, M.

Makhene, M. K.

Nayak, S. U.

Roberts, P. C.

Follmann, D.

Gilbert, P. B.

Coronavirus Variant Immunologic Landscape Trial Study, Team

Journal:
Clin Infect Dis

PMID:
39325506

URL:
https://www.ncbi.nlm.nih.gov/pubmed/39325506

DOI:
10.1093/cid/ciae465

Keywords:
COVID-19 booster Omicron correlate of risk exposure-proximal titer variant vaccine booster

Abstract:
<p>For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.</p>

Go back to Resources